Synairgen

Synairgen SNG

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Synairgen shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Synairgen
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Synairgen
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Synairgen dividends.
Year Amount Change
2006 0.0p
2007 0.0p
0%
2008 0.0p
0%
2009 0.0p
0%
2010 0.0p
0%
2011 0.0p
0%
2012 0.0p
0%
2013 0.0p
0%
2014 0.0p
0%
2015 0.0p
0%
2016 0.0p
0%
2017 0.0p
0%
2018 0.0p
0%
2019 0.0p
0%
2020 0.0p
0%
2021 Sign Up Required

Synairgen Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 18 November 2021
52 Week Low
0.0% on 18 November 2021
Next Ex-Div-Date Countdown
Sign Up Required

About Synairgen

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Sector
Pharmaceuticals & Biotechnology
Country
United Kingdom
Share Price
£1.80 (yesterday's closing price)
Shares in Issue
201 million
Market Cap
£362mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found